Summary & Overview
HCPCS J9297: Pemetrexed (Sandoz) Injection, 10 mg
HCPCS Level II code J9297 designates a 10 mg injection of pemetrexed (Sandoz), identified as not therapeutically equivalent to J9305. This code is used to bill for a specific branded or biosimilar injectable antineoplastic agent administered in outpatient infusion settings and hospital outpatient departments. Nationally, accurate coding of antineoplastic agents affects clinical documentation, payer coverage determinations, and aggregate chemotherapy spending metrics.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for pemetrexed administration, the implications of a non-equivalent product designation, and common billing attributes tied to this HCPCS Level II code. The publication covers benchmarking elements relevant to payers listed above, typical sites of service, and the service type for operational planning.
The briefing highlights where to expect variability in coverage and billing practice for injectable chemotherapy agents, outlines which operational teams should track J9297 utilization, and provides baseline information for payers and provider billing teams. Data not available in the input is indicated where applicable.
Billing Code Overview
HCPCS Level II code J9297 describes an injection of pemetrexed (Sandoz) supplied in 10 mg units. The code specifies that this product is not therapeutically equivalent to J9305, indicating a distinct product reference and billing pathway.
Service type: Chemotherapy drug administration (antineoplastic agent, injectable formulation)
Typical site of service: Outpatient infusion center or hospital outpatient department, consistent with parenteral chemotherapy delivery for oncologic indications.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with newly diagnosed advanced non–small cell lung cancer (NSCLC) presents to the oncology infusion center for systemic chemotherapy. The treatment plan includes pemetrexed-based therapy for non-squamous NSCLC. The patient arrives after pre-treatment laboratory evaluation showing adequate renal function and hematologic parameters. During the visit, nursing verifies premedications (folic acid, vitamin B12, and dexamethasone) and administers the intravenous chemotherapy agent billed with J9297 (pemetrexed, Sandoz). The infusion is delivered in an outpatient oncology infusion suite; the patient is observed for acute infusion reactions, provided post-infusion care instructions, and scheduled for follow-up labs and the next cycle.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (default) | Use when no special circumstances apply to the billed service |
22 | Increased procedural services | Use when unusual effort or time beyond typical pemetrexed administration is documented |